Elicio Therapeutics is a ground-breaking brand that is revolutionizing the fight against aggressive cancers and infectious diseases. Using their innovative Amphiphile technology, they engineer potent vaccines and immunotherapies to target and defeat a wide range of cancers and pathogens. Through a unique combination of materials science and immunology expertise, Elicio's Amphiphile platform develops novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants, and vaccines.

Their pioneering approach focuses on re-engineering the body's immune response to create precision immunity. Elicio's Amphiphiles enable the targeting and concentration of different immunogens in the lymph nodes, resulting in potent T cell and humoral responses. Their lead Amphiphile program, designed for KRAS-driven cancers, will begin patient studies in early 2021.

Elicio's core business is the development of therapeutic cancer vaccines, with their lead clinical program, ELI-002, specifically targeting the KRAS mutations responsible for a quarter of solid tumors. This program is currently undergoing phase 1 clinical studies. Stay up-to-date with Elicio Therapeutics by exploring their pipeline and keeping an eye on their latest news and events.

Join them in their mission to orchestrate the immune response and defeat cancer and infectious diseases